neo, your post is either deliberately deceiving, or you are seriously misinformed. The drug is projected to produce, by many accounts, around $7-9 billion in sales. PCYC owns half of that. At 4.5 billion PCYC is worth at least 3X that number, or 13.5 billion. I'd say with its pipeline it is worth between 160-205 per share today. The breakeven point for JNJ to buy this company at 15 billion ($203 per share), versus split the revenues, on a 100% financed deal at 6%, is around 4-4.5 billion in Ibrutinib sales (at a 40% profit margin), which is as low as 50% of projected sales, plus they are getting a great pipeline. So I believe JNJ will acquire this company for around $15 billion in the next 6 months. But even at $12 billion (which in my view would be the absolute low end), you are looking at $160+ a share. I'll take a 37-71% 6 month gain any day!
As someone pointed out yesterday, it seems as though the whole BioTech Sector is going down. Good for traders since there is good price movement. Wish I was trading it instead of holding it yesterday and today.